Welcome to our dedicated page for Alpha Cognition SEC filings (Ticker: ACOG), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Alpha Cognition Inc. filings document the regulatory record of a British Columbia biopharmaceutical issuer with no-par-value common shares listed on Nasdaq under ACOG. The disclosures identify the company as an emerging growth company and cover formal reporting around ZUNVEYL commercialization, financial results, operational updates, and capital and compensation arrangements.
Recent Form 8-K filings address results of operations, Regulation FD disclosures, board appointments and departures, equity awards under incentive plans, and material agreements tied to legacy Memogain asset and license obligations. Proxy materials describe annual general meeting matters, including director elections, board size, auditor appointment, shareholder voting procedures, and accompanying annual financial statement materials.
Opaleye Management Inc., a 10% owner of Alpha Cognition Inc., reported open‑market purchases of common stock made through Opaleye, L.P. between June 11 and June 15, 2026. The fund bought 2,862 shares at $5.9053, 273 shares at $5.9321, and 4,550 shares at $5.9896 per share.
After these trades, Opaleye, L.P. held 2,652,574 Alpha Cognition shares indirectly attributed to Opaleye Management Inc., while a separately managed account held 90,000 shares. Opaleye Management Inc. may be deemed to beneficially own these securities but disclaims beneficial ownership beyond its pecuniary interest.
Opaleye Management Inc., a ten percent owner of Alpha Cognition Inc., reported indirect open-market purchases of the company’s common stock. Through Opaleye, L.P., it bought 24,856 shares on June 9, 2026 at a weighted average price of $5.9758 and 5,872 shares on June 10, 2026 at $5.9873.
Following these trades, Opaleye, L.P. held 2,644,889 Alpha Cognition shares indirectly, while a separately managed account overseen by Opaleye held 90,000 shares. The firm notes these prices reflect ranges across multiple executions and disclaims beneficial ownership beyond its pecuniary interest in the securities.
Alpha Cognition Inc. insider Opaleye Management Inc., a more than ten percent owner, reported an indirect open-market purchase of 10,054 shares of common stock on June 5, 2026 at a weighted average price of $5.8281 per share, with trades executed between $5.82 and $5.85. These shares are held by Opaleye, L.P., for which Opaleye Management serves as investment manager, bringing that fund’s holdings to 2,614,161 shares of Alpha Cognition common stock. A separately managed account associated with Opaleye Management also holds 90,000 shares. Opaleye Management states it may be deemed to beneficially own these securities but disclaims beneficial ownership except to the extent of its pecuniary interest.
Opaleye Management Inc., a 10% owner of Alpha Cognition Inc., reported a series of indirect open-market purchases of common stock. Through Opaleye, L.P., it bought a total of 73,738 shares on May 27–29, 2026 at prices around $5.73–$5.90 per share.
After these trades, indirect holdings by Opaleye, L.P. increased to 2,604,107 shares of common stock, while a separately managed account holds 90,000 shares. Opaleye Management may be deemed to beneficially own these securities to the extent of its pecuniary interest and expressly disclaims broader beneficial ownership.
Opaleye, L.P., an entity associated with Opaleye Management Inc., reported open-market purchases of Alpha Cognition Inc. common stock. On May 20, 2026, the fund bought 8,431 shares at $5.89 per share, followed by 15,945 shares at $5.70 per share on May 21, 2026.
After these trades, the fund held 2,530,369 shares indirectly, while a separately managed account associated with Opaleye held 90,000 shares. Opaleye Management Inc. disclaims beneficial ownership beyond its pecuniary interest in these positions.
Alpha Cognition Inc. reports an amended joint Schedule 13G/A disclosing ownership by Opaleye-affiliated filers. The Reporting Persons state beneficial ownership of 2,620,369 shares, representing 12.03% of common stock. The filing attributes 2,530,369 shares (11.62%) to Opaleye, L.P. and notes the holdings include shares in a managed account over which voting and dispositive power are shared.
Alpha Cognition Inc. Chief Operating Officer Lauren D'Angelo bought 3,500 Common Shares in an open-market purchase at $5.76 per share. This transaction increased her direct ownership to 140,695 shares, representing a modest expansion of her personal stake in the company.
Opaleye Management Inc., a more than 10% owner of Alpha Cognition Inc., reported additional indirect open-market purchases of the company’s common stock. Through Opaleye, L.P., it bought 17,395 shares at a weighted average price of $5.6926 on May 18 and 16,648 shares at $5.8257 on May 15, for a total of 34,043 shares. Following these trades, Opaleye, L.P. held 2,505,993 shares, and a separately managed account overseen by Opaleye held 90,000 shares. The filing notes that Opaleye Management may be deemed to beneficially own these securities but disclaims beneficial ownership beyond its pecuniary interest.
Alpha Cognition Inc. reported first-quarter 2026 results showing early commercial traction but higher losses. Total revenue was $3.53 million, up 21% year over year, driven by a jump in ZUNVEYL product sales to $3.50 million, while licensing revenue fell to $0.03 million.
Operating expenses rose to $11.63 million, mainly from expanding sales, marketing, and headcount to support the ZUNVEYL launch, resulting in a net loss of $6.48 million versus $1.73 million a year earlier. Cash and cash equivalents were $54.25 million, and management believes this is sufficient for at least 12 months, though additional capital will likely be needed for ongoing commercialization and R&D.
The company disclosed a material weakness in internal control over financial reporting related to complex instruments and segregation of duties and is implementing enhanced review procedures and external technical support. Alpha Cognition remains focused on building the ZUNVEYL franchise and advancing its preclinical neurodegenerative pipeline.
Alpha Cognition Inc. files Amendment No. 1 to a Schedule 13G/A reporting beneficial ownership stakes held by affiliated entities and individuals. The filing lists Manchester Management Company, LLC with 919,935 shares (4.2%), Manchester Management PR, LLC with 919,935 shares (4.2%), James E. Besser with 1,076,935 shares (4.9%), and Morgan C. Frank with 888,935 shares (4.0%).
The filing states that all reported securities are directly owned by advisory clients of Manchester Management PR, LLC and includes a Joint Filing Agreement. The signatures are dated 05/12/2026.